SEMA6B

Across TCGA pan-cancer cohorts, SEMA6B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SEMA6B data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SEMA6B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SEMA6B expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, GBM, and LUAD are the cancer types where SEMA6B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.875	0.487	<.001	81	view →
GBM	DFS	Tertile	All	0.837	0.556	.002	17	view →
LUAD	DFS	Tertile	All	0.365	0.881	.011	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SEMA6B–HNSC (DFS)

Open the HNSC breakdown →